论文部分内容阅读
目的 探讨可溶性白细胞介素２ 受体（ｓＩＬ－ ２Ｒ） 在原发性肝癌（ＰＬＣ） 患者中的临床意义。方法采用双抗体夹心ＥＬＩＳＡ法检测对照组４０ 例，健康献血员和疾病组１０５ 例ＰＬＣ患者血清ｓＩＬ－ ２Ｒ水平（ 其中Ⅰ、Ⅱ、Ⅲ期肝癌患者分别为２２ 例、４１ 例、４２ 例） 以及１８ 例手术切除肿瘤后和１８ 例栓塞化疗（ＴＡＥ） 后动态检测观察。结果 ＰＬＣ患者血清ｓＩＬ－ ２Ｒ平均水平（７５９．７ ±２５０．９ ｕ／ｍｌ） 明显高于对照组（２６９．７ ±５８．６ ｕ／ｍｌ） ；Ⅰ、Ⅱ、Ⅲ期ＰＬＣ患者ｓＩＬ－ ２Ｒ水平依次增高（ Ｐ＜０．０１） ；ｓＩＬ－ ２Ｒ水平＞１０００ ｕ／ｍｌ、５００ ～１０００ ｕ／ｍｌ 和＜ ５００ ｕ／ｍｌ 者一年生存率分别为３３％ 、６４ ％ 和１００ ％ 。手术切除肿瘤后和ＴＡＥ治疗后肿瘤缩小的患者ｓＩＬ－ ２Ｒ水平比治疗前均明显降低（Ｐ＜０．０１） 。结论 检测ｓＩＬ－ ２Ｒ水平对了解ＰＬＣ患者体内肿瘤体积大小、病程发展、免疫状态和疗效评价及其预后估计具有重要参考价值。
Objective To investigate the clinical significance of soluble interleukin 2 receptor (sIL-2R) in primary liver cancer (PLC) patients. Methods Serum sIL-2R levels were detected in 40 controls, healthy blood donors and 105 PLC patients in the control group by double-antibody sandwich ELISA (22, 41 and 42 patients with stage I, II, and III liver cancer, respectively). Eighteen patients underwent surgical resection and 18 patients underwent dynamic detection after embolization chemotherapy (TAE). Results The serum level of sIL-2R in PLC patients was significantly higher than that in the control group (759.7 ± 250.9 u/ml) (269.7 ± 58.6 u/ml); sIL-2R in PLC patients with stage I, II, and III The levels increased sequentially (P<0.01); the one-year survival rates of sIL-2R levels> 1000 u/ml, 500-1000 u/ml, and <500 u/ml were 33%, 64%, and 100%, respectively. The level of sIL-2R in patients with tumor resection after TAE surgery and after TAE treatment was significantly lower than before treatment (P<0.01). Conclusion The detection of sIL-2R level has important reference value for understanding tumor size, course of disease progression, immune status, curative effect evaluation and prognosis estimation in PLC patients.